Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
25 drugs in development
By Therapeutic Area
top 6
R&D Momentum
83/100
Pipeline Velocity
57/100
Trial Completion Rate
75/100
Pipeline Concentration
15/100
Pipeline Freshness
66/100
Strategic Signals
Activity
Last 14 days
Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering
Comprehensive Neuroimaging and Molecular Biomarkers of Neurotoxicity Following CAR T-Cell Therapy
Enhancing Gamma Band Response in Mild Cognitive Impairment to Improve Working Memory
Sustained Auricular Nerve Stimulation for PVC Suppression
Prospective Single-center Study Comparing Thulium Fiber Laser to Pulsed Thulium:YAG Laser in the Ureteroscopic Treatment of Nephrolithiasis
Refining and Implementing Technology-Enhanced Family Navigation to Promote Early Access and Engagement With Mental Health Services for Youth With Autism
Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)
Leveraging Artificial Intelligence and Multi-Omics Data to Predict Opioid Addiction
Ultrasound-guided Percutaneous Cryoneurolysis for Management of Chronic Painful Diabetic Neuropathy: A Randomized Sham-controlled Pilot Study
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)